Prog Mol Biol Transl Sci. 2021 ;pii: S1877-1173(20)30173-3. [Epub ahead of print]178 213-229
The clustered regularly interspaced short palindromic repeats (CRISPR), and CRISPR-associated (Cas) protein technologies have evolved as promising, cost-effective, and efficient methods for editing genomes. Editing genomes with high specificity and precision is a daunting task, where errors can lead to undesirable outcomes. Many elegant studies have successfully shown that the CRISPR-Cas9 system can modify, disrupt, and add new DNA sequences directly into the genomes of the cells or animals being studied. As such, the CRISPR-Cas9 technology holds immense potential for biomedical research as well as agricultural and therapeutic applications, further emphasized by its unprecedented movement into the clinical setting. Throughout every stage of life, missense mutations can lead to highly unfavorable outcomes, syndromes, and diseases. Many of these mutations are transferred directly through the fertilization process and, thereby, acquired at birth and propagated to the next generation. As such, it has been of great interest to develop techniques to repair these mutations using genetic manipulation, prior to or following birth. CRISPR-Cas9 has many advantages in this regard over numerous other existing technologies. Regardless, editing bases within a genome can be associated with numerous challenges that were previously unrecognized and lead to unforeseen consequences. While the CRISPR-Cas9 method is perfectly suitable for editing cells outside the body with limited risk to the normal functioning of the cell, recent publications have illustrated a number of challenging conditions resulting from its use. One of them is directed to the host immune response toward CRISPR-Cas9. With this in mind, this review will discuss recent observations on the host immune response to CRISPR-Cas9 and the associated challenges that arise as a result.
Keywords: B cell; CRISPR-Cas; MHC; T cell; Therapeutic application